Facilitador de Control de Calidad

AstraZeneca strikes up to $1.5 billion AI drug discovery deal with Insitro. Published on 10/15/2026 at 08:42 am EDT - Modified on 10/15/2026 at 08:50 am EDT By Adria Calatayud AstraZeneca said it is teaming up with startup Insitro to deploy artificial intelligence to explore new treatments for cardiometabolic diseases in a deal valued at as much as $1.5 billion. The U.K. drugmaker will pay AI therapeutics company Insitro $40 million upfront and up to $1.46 billion subject to meeting development and commercial targets, in exchange for the exclusive worldwide rights to advance programs identified as part of the partnership, the companies said Thursday. Insitro will also be eligible to receive royalties based on potential sales, they added. AstraZeneca said the collaboration would focus on difficult-to-treat cardiometabolic diseases such as metabolic dysfunction-associated steatohepatitis, also known as fatty liver disease, and cardiomyopathies. Under the deal, Insitro will use its AI platform to identify the root cause of disease and advance AstraZeneca-nominated targets, the companies said. Insitro said AstraZeneca would lead all clinical development, regulatory work, as well as commercialization activities. The partnership marks the latest to pair pharmaceutical and AI companies, as drugmakers turn to the technology in a bid to speed up the discovery and development of new medicines. Wegovy maker Novo Nordisk last month said it would partner with Anthropic to use the AI lab's science-specific platform, known as Claude Science, for drug research. Rival Roche earlier this year said it would build a supercomputer in partnership with Nvidia. Write to Adria Calatayud at [email protected] (END) Dow Jones Newswires 10-15-26 0835ET (C) Dow Jones - 2026

AstraZeneca strikes $40 million AI drug discovery deal with insitro. 1 hour ago 44 LONDON, Oct 15: AstraZeneca has teamed up with artificial intelligence biotech company insitro to discover and develop new treatments for difficult to treat liver and heart conditions, the British drugmaker said on Thursday. Under the agreement, AstraZeneca will pay $40 million up front, with California-based insitro eligible for up to about $1.46 billion in potential development and commercial milestones, as well as a single-digit percentage of future sales in royalties. The multi-year collaboration will focus on metabolic dysfunction-associated steatohepatitis (MASH), a severe liver disease, and cardiomyopathies, a group of diseases that affect the heart muscle. Both have historically lacked effective therapies because researchers have struggled to pinpoint their root biological drivers, the drugmaker said. Insitro will use its "Virtual Human" AI platform, which combines lab-grown cell models and machine learning, to identify causal disease biology and advance AstraZeneca-nominated targets from discovery to development-candidate stage. AstraZeneca will then run and fund future clinical trials. The deal builds on insitro's expansion across the pharmaceuticals industry. The biotech company recently expanded its partnership with Bristol Myers Squibb to advance a broader portfolio of targets for amyotrophic lateral sclerosis (ALS). It also teamed up with Eli Lilly to build AI models that predict pharmacological properties of small molecules in living organisms. "Choosing the new targets that we want to put into our discovery pipeline is one of the hardest things we do across research and development," Sharon Barr, executive vice president of biopharmaceuticals R&D at AstraZeneca, told Reuters. "By the time we read about a new pathway or target (in major scientific journals), it is no longer novel. It's in the public domain and we're already a few steps too late. But when we identify these unique connections early and test them in cellular systems, we're ahead of the game." Barr added that pairing AI tools with experienced scientists allows the company to test fewer molecules in the lab, reduce guesswork and speed the search for effective medicines.

AstraZeneca strikes $40 million AI drug discovery deal with insitro. Posted on October 15, 2026 · Last updated: October 15, 2026 AstraZeneca and insitro launch $40 million ai-driven drug discovery deal. AI collaboration targets liver and heart diseases. By Patrick Wingrove Overview of the partnership. LONDON, Oct 15 (Reuters) - AstraZeneca has teamed up with artificial intelligence biotech company insitro to discover and develop new treatments for difficult to treat liver and heart conditions, the British drugmaker said on Thursday. Financial terms and potential milestones. Under the agreement, AstraZeneca will pay $40 million up front, with California-based insitro eligible for up to about $1.46 billion in potential development and commercial milestones, as well as a single-digit percentage of future sales in royalties. Focus areas and technology. Targeted diseases: MASH and cardiomyopathies. The multi-year collaboration will focus on metabolic dysfunction-associated steatohepatitis (MASH), a severe liver disease, and cardiomyopathies, a group of diseases that affect the heart muscle. Both have historically lacked effective therapies because researchers have struggled to pinpoint their root biological drivers, the drugmaker said. AI platform: Virtual Human. Insitro will use its "Virtual Human" AI platform, which combines lab-grown cell models and machine learning, to identify causal disease biology and advance AstraZeneca-nominated targets from discovery to development-candidate stage. AstraZeneca will then run and fund future clinical trials. Insitro's growing industry presence. Recent partnerships. Bristol Myers Squibb collaboration. The deal builds on insitro's expansion across the pharmaceuticals industry. The biotech company recently expanded its partnership with Bristol Myers Squibb to advance a broader portfolio of targets for amyotrophic lateral sclerosis (ALS). Eli Lilly AI model initiative. It also teamed up with Eli Lilly to build AI models that predict pharmacological properties of small molecules in living organisms. Expert insights. Challenges in drug discovery. "Choosing the new targets that we want to put into our discovery pipeline is one of the hardest things we do across research and development," Sharon Barr, executive vice president of biopharmaceuticals R&D at AstraZeneca, told Reuters. "By the time we read about a new pathway or target (in major scientific journals), it is no longer novel. It's in the public domain and we're already a few steps too late. But when we identify these unique connections early and test them in cellular systems, we're ahead of the game." AI and scientific expertise. Barr added that pairing AI tools with experienced scientists allows the company to test fewer molecules in the lab, reduce guesswork and speed the search for effective medicines. (Reporting by Patrick Wingrove in LondonEditing by David Goodman) Key takeaways. * AstraZeneca invests $40 million upfront in AI drug discovery for liver (MASH) and heart (cardiomyopathy) diseases previously lacking effective therapies. * Insitro's Virtual Human(TM) platform combines lab-grown cell models and machine learning to uncover causal disease biology and accelerate target development. * The deal could yield insitro up to $1.46 billion in milestones and royalties, and builds on its growing AI collaboration portfolio with Bristol Myers Squibb and Eli Lilly. Frequently asked questions. What is the focus of the AstraZeneca and insitro partnership? How much is AstraZeneca investing in the insitro deal? What technology will insitro use in the collaboration? Who will conduct clinical trials for the discovered treatments? What diseases are being targeted in this AI-driven drug discovery project?